慢性阻塞性肺疾病急性加重分类对未来急性加重的判别性能与临床效用
在COPDGene(n=3035)和NOVELTY(n=3080)队列中,评估18种基于1年或2年回顾期的COPD急性加重频率分类对未来12个月发生至少2次中度或1次重度急性加重的预测性能。过去2年内任何中度或重度急性加重分类的AUC最高(COPDGene 0.69,NOVELTY 0.87),显著优于现行标准。结论:过去2年至少1次中度或重度急性加重具有最佳判别力和临床效用。
要点
- 过去2年内任何中度或重度急性加重对预测未来急性加重具有最高判别力。
- 该分类优于现行标准(过去1年至少2次中度或1次重度急性加重)。
- 在5%-30%治疗阈值范围内,滚动2年窗口定义的加重模式净获益最高。
核心结论
- 过去2年内至少1次中度或1次重度急性加重对预测未来高急性加重风险具有最高判别力和临床效用。
研究设计与样本
- 基于COPDGene(n=3035)和NOVELTY(n=3080)两个队列的分析。
- 对1年和2年回顾期,估计6种不同的急性加重频率分类,每种通过3种方式确定:1年内、连续2年每年、滚动合并2年期间,共18种分类。
- 评估18种分类预测未来12个月发生2次中度或1次重度急性加重的AUC和净获益。
主要发现
- COPDGene中,过去2年任何中度或重度急性加重分类的AUC=0.69(95%CI 0.67-0.71)。
- NOVELTY中,该分类的AUC=0.87(95%CI 0.85-0.88)。
- 在5%-30%临床相关治疗阈值范围内,滚动2年窗口定义的加重模式净获益最高。
关键数值与推荐
- 过去2年内任何中度或重度急性加重分类的AUC最高:COPDGene 0.69(95%CI 0.67-0.71),NOVELTY 0.87(95%CI 0.85-0.88)。
- 净获益分析中,滚动2年窗口定义的加重模式在5%-30%治疗阈值范围内净获益最高。
临床怎么用
- 识别高急性加重风险患者时,可考虑采用过去2年内至少1次中度或1次重度急性加重这一分类。
- 该分类判别力和临床效用优于现行基于过去1年的高风险标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Treatment initiation or intensification to prevent exacerbations of chronic obstructive pulmonary disease (COPD) is based on the identification of patients with high exacerbation risk. The commonly used high-risk category of at least 2 moderate or 1 severe exacerbation within the prior 12 months has limited supporting evidence. OBJECTIVE: To test the discriminative performance and assess the clinical utility of various COPD exacerbation categories for predicting future exacerbations. METHODS: In the Genetic Epidemiology of COPD (COPDGene) and NOVEL observational longitudinal study (NOVELTY) cohorts, for each 1-year and 2-year recall periods, we estimated 6 distinct categories of exacerbation frequencies (based on distinct combinations of the number of moderate and severe events), each ascertained in 3 ways: within 1 year, in each of 2 consecutive years, and over a rolling combined 2-year period. We estimated the area under the receiver operating characteristic curve (AUC) and net benefit to evaluate, respectively, the discriminative performance and clinical utility of the resulting 18 categories for predicting the occurrence of 2 moderate or 1 severe exacerbation in the next 12 months. MEASUREMENTS AND MAIN RESULTS: In both COPDGene (n = 3035) and NOVELTY (n = 3080), the category of any moderate or severe exacerbation in the past 2 years had the highest AUC (COPDGene: AUC = 0.69; 95% confidence interval [CI], 0.67-0.71; NOVELTY: AUC = 0.87; 95% CI, 0.85-0.88) for predicting the outcome. The AUC was significantly higher than that of the current standard of at least 2 moderate or at least 1 severe exacerbations in the past year (ΔAUC = 0.03 in COPDGene, and ΔAUC = 0.12 in NOVELTY; both P < .001). In net benefit analysis, exacerbation patterns defined over rolling 2-year windows provided the highest net benefit across a clinically relevant treatment threshold range of 5%-30%. CONCLUSIONS: At least 1 moderate or 1 severe exacerbation over the previous 2 years has the highest discrimination and confers the highest clinical utility for predicting high COPD exacerbation risk.
引用
- Bhatt, Adibi, Bodduluri, et al. Discriminative performance and clinical utility of chronic obstructive pulmonary disease exacerbation categories for predicting future exacerbations. Am J Respir Crit Care Med. 2026. PMID: 42085195. doi:10.1093/ajrccm/aamag118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。